

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10569315
	Filing Date		2008-04-28
	First Named Inventor	Gerard M. Housey	
	Art Unit	1624	
	Examiner Name	Ward, Paul V.	
	Attorney Docket Number	00395/45	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	3647858		1972-03-07	Hinkley et al.	
	2	3887699		1975-06-03	Yolles	
	3	3940486		1976-02-24	Fitzi	
	4	4180662		1979-12-25	Pfister et al.	
	5	4233299		1980-11-11	Trummlitz et al.	
	6	4500637		1985-02-19	Neville et al.	
	7	4695459		1987-09-22	Steinman et al.	
	8	4714613		1987-12-22	Shouval et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10569315
Filing Date	2008-04-28
First Named Inventor	Gerard M. Housey
Art Unit	1624
Examiner Name	Ward, Paul V.
Attorney Docket Number	00395/45

9	4929616		1990-05-29	Binder et al	
10	5138072		1992-08-11	Wagner	
11	5260200		1993-11-09	Kahn et al.	
12	5380738		1995-01-10	Norman et al.	
13	5578590		1996-11-26	Grunicke et al.	
14	5665543		1997-09-09	Foulkes et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

U.S.PATENT APPLICATION PUBLICATIONS

[Remove](#)

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
-------------------	---------	--------------------------------------	---------------------------	------------------------	------------------	---	--	----------------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10569315
Filing Date		2008-04-28
First Named Inventor	Gerard M. Housey	
Art Unit		1624
Examiner Name	Ward, Paul V.	
Attorney Docket Number		00395/45

	1	86/04613	WO		1986-08-14	United States of America, et al.		<input type="checkbox"/>
	2	88/03168	WO		1988-05-05	The Salk Institute For Biological Studies, et al.		<input type="checkbox"/>
	3	89/03687	WO		1989-05-05	Genetics Institute, Inc., et al.		<input type="checkbox"/>
	4	89/07654	WO		1989-08-24	Progenics Pharmaceuticals, Inc. et al.		<input type="checkbox"/>
	5	94/13635	WO		1994-06-23	Merck Frosst Canada Inc., et al.		<input type="checkbox"/>
	6	94/15932	WO		1994-07-21	G.D. Searle & Co., et al.		<input type="checkbox"/>
	7	94/23714	WO		1994-10-27	Toyama Chemical Co., Ltd., et al.		<input type="checkbox"/>
	8	94/26731	WO		1994-11-24	Merck Frosst Canada, Inc., et al.		<input type="checkbox"/>
	9	94/27980	WO		1994-12-08	G.D. Searle & CO., et al.		<input type="checkbox"/>
	10	0325849	EP	B1	1989-08-02	The Salk Institute for Biological Studies, et al.		<input type="checkbox"/>
	11	0327369	EP	A2	1989-08-09	The Regents of the University of California, et al		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10569315
Filing Date		2008-04-28
First Named Inventor	Gerard M. Housey	
Art Unit	1624	
Examiner Name	Ward, Paul V.	
Attorney Docket Number	00395/45	

12	0246882	EP	A2	1987-11-25	Dana-Farber Cancer Institute,et al.		<input type="checkbox"/>
13	0251612	EP	A2	1988-01-07	Genetic Systems Corporation,et al.		<input type="checkbox"/>
14	0249390	EP	A2	1987-12-16	Pert, C. et al.		<input type="checkbox"/>
15	0247557	EP	A2	1987-12-02	F. Hoffmann-LA Roche & Co., et al.		<input type="checkbox"/>
16	0219106	EP	A2	1987-04-22	F. Hoffmann-LA Roche & Co., et al.		<input type="checkbox"/>
17	0214709	EP	A2	1986-04-29	United Biomedical Inc., et al.		<input type="checkbox"/>
18	0187041	EP	A1	1986-07-09	Genentech, Inc. et al.		<input type="checkbox"/>
19	0058481	EP	A1	1982-08-25	Imperial Chemical Industries Plc et al.		<input type="checkbox"/>
20	0133988	EP	A2	1985-04-13	Hoechst Aktiengesellschaft, et al.		<input type="checkbox"/>
21	0158277	EP	A2	1985-10-16	Hoechst Aktiengesellschaft, et al.		<input type="checkbox"/>
22	0171496	EP	A2	1986-02-19	Research Development Corporation of Japan et al.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10569315
Filing Date	2008-04-28
First Named Inventor	Gerard M. Housey
Art Unit	1624
Examiner Name	Ward, Paul V.
Attorney Docket Number	00395/45

23	0184187	EP	A2	1986-06-11	Teijin Limited et al.		<input type="checkbox"/>
24	0194276	EP	B1	1993-08-11	Cell-Tech Limited, et al.		<input type="checkbox"/>
25	0695547	EP	A1	1996-02-07	Toyama Chemical Co. Ltd., et al		<input type="checkbox"/>
26	1176565	CA		1984-10-23	Kent, J. et al		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button **Add**

NON-PATENT LITERATURE DOCUMENTS

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	AKIYAMA, S., et al., "Isolation and genetic characterization of human KB cell lines resistant to multiple drugs." Somat Cell Mol Genet (1985), Vol. 11(2), pp. 117-26.	<input type="checkbox"/>
	2	AMMANN, A.J., et al., "Acquired immune dysfunction in homosexual men: immunologic profiles." Clin. Immunol. Immunopathol. (1983), Vol. 27(3), pp. 315-25.	<input type="checkbox"/>
	3	AYUSAWA, D., et al., "Selection of mammalian thymidine auxotrophic cell mutants defective in thymidylate synthase by their reduced sensitivity to methotrexate." Somatic Cell Genet (1981), Vol. 7, pp. 523-534.	<input type="checkbox"/>
	4	AYUSAWA, D. et al., "Single step selection of mouse FM3A cell mutants defective in thymidylate synthetase." Somatic Cell Genet. (1980), Vol. 6, pp. 261-270.	<input type="checkbox"/>
	5	BALZARINI, J. et al., "Strategies for the measurement of the inhibitory effects of thymidine analogs on the activity of thymidylate synthase in intact murine leukemia L1210 cells." Biochim Biophys Acta (1984), Vol. 785, pp. 36-45.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10569315
Filing Date	2008-04-28
First Named Inventor	Gerard M. Housey
Art Unit	1624
Examiner Name	Ward, Paul V.
Attorney Docket Number	00395/45

6	BALZARINI, J. et al., "Thymidylate synthetase positive and negative murine mammary FM3A carcinoma cells as a useful system for detecting thymidylate synthetase inhibitors." FEBS Lett. (1984), Vol. 173, pp. 227-232.	<input type="checkbox"/>
7	BALZARINI, J. et al., "Thymidylate synthetase deficient mouse FM3A mammary carcinoma cell line as a tool for studying the thymidine salvage pathway and the incorporation of thymidine analogues into host cell DNA." Biochem. J. (1984), Vol. 217, pp. 245-252.	<input type="checkbox"/>
8	BALZARINI, J. et al., "Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E) 5 (2 bromovinyl) 2' deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene." Mol. Pharmacol. (1987), Vol. 32, pp. 410-416.	<input type="checkbox"/>
9	BARRE SINOUSI, F. et al., "Isolation of a T lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)." Science (1983) Vol. 220(4599), pp. 868-871.	<input type="checkbox"/>
10	BARTUS, H.R. et al., "Improved genetically modified Escherichia coli strain for prescreening antineoplastic agents." Antimicrob. Agents Chemother. (1984), Vol. 25, pp. 622-625.	<input type="checkbox"/>
11	BECK, W.T., "Cellular pharmacology of Vinca alkaloid resistance and its circumvention." Adv. Enzyme Regul. (1984), Vol. 22, pp. 207-227.	<input type="checkbox"/>
12	BENDER, P.E. et al., "5,6 Diaryl 2,3 dihydroimidazo[2,1 b]thiazoles: a new class of immunoregulatory antiinflammatory agents." J. Med. Chem. (1985), Vol. 28, pp. 1169-1177.	<input type="checkbox"/>
13	BIGNAMI, M. et al., "Tumor promoters enhance v myc induced focus formation in mammalian cell lines." Ann. N. Y. Acad. Sci. (1987), Vol. 511, pp. 343-349.	<input type="checkbox"/>
14	BINDER, D. et al., "Analogues and derivatives of tenoxicam. 1. Synthesis and antiinflammatory activity of analogues with different residues on the ring nitrogen and the amide nitrogen." J. Med. Chem. (1987), Vol. 30, pp. 678-682.	<input type="checkbox"/>
15	BLYTHIN, D.J. et al., "Antiinflammatory activity of substituted 6 hydroxypyrimido[2,1 f]purine-2,4,8(1H,3H,9H) triones. Atypical nonsteroidal antiinflammatory agents." J. Med. Chem. (1986), Vol. 29, pp. 1099-1113.	<input type="checkbox"/>
16	BOULIANNE, G.L. et al., "Production of functional chimaeric mouse/human antibody." Nature (1984), Vol. 312(5995), pp. 643-646.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10569315
Filing Date	2008-04-28
First Named Inventor	Gerard M. Housey
Art Unit	1624
Examiner Name	Ward, Paul V.
Attorney Docket Number	00395/45

17	BOWEN, D.L. et al., "Immunopathogenesis of the acquired immunodeficiency syndrome." Ann. Intern. Med. (1985), Vol. 103, pp. 704-709.	<input type="checkbox"/>
18	BRADFORD, M.M et al., "A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding." Anal. Biochem. (1976), Vol. 72, pp. 248-254.	<input type="checkbox"/>
19	BROOKS, K.H. et al., "Recombinant IL 2 but not recombinant interferon gamma stimulates both proliferation and IgM secretion in a Ly 1+ clone of neoplastic murine B cells (BCL1)." J. Immunol. (1986), Vol. 137, pp. 3205-3210.	<input type="checkbox"/>
20	BUZAS, A. et al., "Sur la chlorosulfonylation du thiophene et de quelques uns de ses derives substitues." Bulletin De la Societe Francaise de Cancerologie (1960) pp. 793-803.	<input type="checkbox"/>
21	CHIAINI, J. et al., "Excretion and metabolism of a nonsteroidal antiinflammatory agent, 4 hydroxy 2 methyl 2H 1,2 benzothiazine-3 carboxanilide 1,1 dioxide, in rat, dog, monkey, and man." J. Med. Chem. (1971), Vol. 14, pp. 1175-1177.	<input type="checkbox"/>
22	CHAKRABARTY, S. et al., "Restoration of normal growth control and membrane antigen composition in malignant cells by N,N dimethylformamide." Cancer Res. (1984) Vol. 44, pp. 2181-2185.	<input type="checkbox"/>
23	CHANH, T.C. et al., "Induction of anti HIV neutralizing antibodies by synthetic peptides." EMBO J. (1986), Vol. 5, pp. 3065-3071.	<input type="checkbox"/>
24	CHEN, Y.C. et al., "Properties of mammalian cells transformed by temperature sensitive mutants of avian sarcoma virus." Cell (1977), Vol.11, pp. 513-521.	<input type="checkbox"/>
25	CHEN, W.-T. et al., "Regulation of fibronectin receptor distribution by transformation, exogenous fibronectin, and synthetic peptides." J. Cell Biol. (1986), Vol. 103, pp. 1649-1661.	<input type="checkbox"/>
26	COLE, S.P.C. et al., "The EBV-Hybridoma Technique and its Application to Human Lung Cancer." In: Monoclonal Antibodies and Cancer Therapy, pp. 77-96 (R. Reisfeld & S. Sell, eds., Alan R. Liss, N.Y. 1985)	<input type="checkbox"/>
27	COLLARD, J.G. et al., "Invasive and metastatic potential induced by ras transfection into mouse BW5147 T lymphoma cells." Cancer Res. (1987), Vol. 47, pp. 754-759.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10569315
Filing Date		2008-04-28
First Named Inventor	Gerard M. Housey	
Art Unit	1624	
Examiner Name	Ward, Paul V.	
Attorney Docket Number	00395/45	

28	CONSONNI, R. et al., "Reactivity of 2-Methyl-4-(1-pyrrolidinyl)-2H-1,2-benzothiazine 1,1-dioxide towards p-Toluenesulphonyl Azide." J. Heterocyclic Chem. (1990), Vol.27, pp. 427-430.	<input type="checkbox"/>
29	CROFFORD, L.J. "COX 1 and COX 2 tissue expression: implications and predictions." J. Rheumatol. (1997) 24 Suppl 49, pp. 15-19.	<input type="checkbox"/>
30	CUNNINGHAM RUNDLES, "Serum suppression of lymphocyte activation in vitro in acquired immunodeficiency disease." J. Clin. Immunol. (1983), Vol. 3, pp. 156-165.	<input type="checkbox"/>
31	CUTTITTA, F. et al., "Bombesin like peptides can function as autocrine growth factors in human small cell lung cancer." Nature (1985), Vol. 316(6031), pp. 823-826.	<input type="checkbox"/>
32	DALGLEISH, A.G. et al., "The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus." Nature (1984), Vol. 312(5996), pp. 763-767.	<input type="checkbox"/>
33	DAVIES, T. "Magic bullets." Nature (1981), Vol. 289(5793), pp. 12-13.	<input type="checkbox"/>
34	DE CLERCQ, E. et al., "Potent activity of 5 fluoro 2' deoxyuridine and related compounds against thymidine kinase deficient (TK) herpes simplex virus: targeted at thymidylate synthase." Mol. Pharmacol. (1987), Vol. 32, pp. 286-292.	<input type="checkbox"/>
35	DE CLERCQ, E. et al., "Thymidylate synthetase as target enzyme for the inhibitory activity of 5 substituted 2' deoxyuridines on mouse leukemia L1210 cell growth." Mol. Pharmacol. (1981), Vol. 19, pp. 321-330.	<input type="checkbox"/>
36	DELCLOS, K.B. et al., "Specific labeling of mouse brain membrane phospholipids with [20-3H]phorbol 12-p-azidobenzoate 13-benzoate, a photolabile phorbol ester." Proc. Natl. Acad. Sci. USA (1983), Vol. 80, pp. 3054-3058.	<input type="checkbox"/>
37	DUTTA-ROY, A.K. et al., "Prostacyclin stimulation of the activation of blood coagulation factor X by platelets." Science (1986), Vol. 231(4736), pp. 385-8.	<input type="checkbox"/>
38	ELROY-STEIN, O. et al., "Overproduction of human Cu/Zn superoxide dismutase in transfected cells: extenuation of paraquat mediated cytotoxicity and enhancement of lipid peroxidation." EMBO J. (1986), Vol. 5, pp. 615-622.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10569315
Filing Date	2008-04-28
First Named Inventor	Gerard M. Housey
Art Unit	1624
Examiner Name	Ward, Paul V.
Attorney Docket Number	00395/45

39	ERIKSON, R.L., "Towards a biochemical description of malignant transformation. Identification and functional characterization of the Rous sarcoma virus transforming gene product." Cancer (1984), Vol. 53, pp. 2041-2045.	<input type="checkbox"/>
40	FAUCI, A.S., "Immunologic abnormalities in the acquired immunodeficiency syndrome (AIDS)." Clin. Res. (1984), Vol. 32, pp.491-499.	<input type="checkbox"/>
41	FISHER, P.B. et al., "Modulation of differentiation in murine and human cells by interferon and phorbol ester tumor promoters." In: Pigment Cell 1985. Biological, Molecular and Clinical Aspects of Pigmentation (Bagnara, J., Klaus, S. N., Paul, E. & Scharl, M. eds., University of Tokyo Press) p. 325-332.	<input type="checkbox"/>
42	FISHER, P.B. et al., "Interactions between initiating chemical carcinogens, tumor promoters, and adenovirus in cell transformation." Teratog. Carcinog. Mutagen. (1980) Vol. 1, pp. 245-257.	<input type="checkbox"/>
43	FRAGA, C.A.M. et al., "The synthesis of a new benzothiazine derivative, related to oxicams, synthesized from natural safole." J. Heterocyclic Chem (1992), Vol. 29, pp. 1667-1669.	<input type="checkbox"/>
44	FU, J.Y. et al., "The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes." J. Biol. Chem. (1990), Vol. 265(28), pp. 16737-40.	<input type="checkbox"/>
45	FUKAZAWA, H. et al., "Effects of herbimycin A and various SH-reagents on p60v-src kinase activity in vitro." Biochem Biophys Res Commun. (1990), Vol.173(1), pp. 276-82.	<input type="checkbox"/>
46	FUKAZAWA, H. et al., "Specific inhibition of cytoplasmic protein tyrosine kinases by herbimycin A in vitro." Biochem. Pharmacol. (1991), Vol. 42(9), pp. 1661-71.	<input type="checkbox"/>
47	FULTON, R.J. et al., "Purification of ricin A1, A2, and B chains and characterization of their toxicity." J. Biol. Chem. (1986), Vol. 261, pp. 5314-5319.	<input type="checkbox"/>
48	FUNG, M.S.C. et al., "Monoclonal antibodies that neutralize HIV-1 virions and inhibit syncytium formation by infected cells." Bio/technology (1987), Vol. 5, pp. 940-946.	<input type="checkbox"/>
49	GALLO, R.C. et al., "Frequent detection and isolation of cytopathic retroviruses (HTLV III) from patients with AIDS and at risk for AIDS." Science (1984), Vol. 224(4648), pp. 500-503.	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10569315
	Filing Date		2008-04-28
	First Named Inventor	Gerard M. Housey	
	Art Unit	1624	
	Examiner Name	Ward, Paul V.	
	Attorney Docket Number	00395/45	

	50	GILL, G.N. et al., "Monoclonal anti epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor stimulated tyrosine protein kinase activity." J. Biol. Chem. (1984), Vol. 259, pp. 7755-7760.	<input type="checkbox"/>
--	----	---	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button **Add**

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10569315
Filing Date	2008-04-28
First Named Inventor	Gerard M. Housey
Art Unit	1624
Examiner Name	Ward, Paul V.
Attorney Docket Number	00395/45

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Lawrence P. Casson/	Date (YYYY-MM-DD)	2011-11-21
Name/Print	Lawrence P. Casson	Registration Number	46606

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.